Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 2017
October 17 2017 - 9:15AM
YASTEST
OXFORD, United Kingdom and MARLBOROUGH,
Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global
PLC (Nasdaq:OXFD), a global, high-growth diagnostics company
focused on developing and commercializing proprietary tests for the
management of underserved immune-regulated conditions, today
announced that it plans to release third quarter 2017 financial
results prior to market open on Tuesday, October 31, 2017.
Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick
Altieri, Chief Financial Officer, will host a conference call to
review the Company's results at 8:00 a.m. Eastern Time the same
day. The call will be concurrently webcast.
To listen to the conference call on your
telephone, please dial (855) 363-5047 for United States callers and
+1 (484) 365-2897 for international callers and reference
confirmation code 99539511, approximately ten minutes prior to
start time. To access the live audio webcast or subsequent
archived recording, visit the Investor Relations section of Oxford
Immunotec's website at www.oxfordimmunotec.com. The
replay will be available on the Company's website for approximately
60 days.
About Oxford
Immunotec
Oxford Immunotec Global PLC is a global,
high-growth diagnostics company focused on developing and
commercializing proprietary tests for the management of underserved
immune-regulated conditions. The Company's first product is
the T-SPOT®.TB test, which is used to
test for tuberculosis infection. The T-SPOT.TB test has been approved for sale in over 50
countries, including the United States, where it has received
pre-market approval from the Food and Drug Administration, Europe,
where it has obtained a CE mark, as well as Japan and China.
The Company's second product line is a range of assays for
tick-borne diseases, such as Lyme disease, obtained through the
acquisitions of Imugen and Immunetics. Also obtained through
the acquisitions is the Company's third product line focused on
screening for Babesia in donated blood, for which the Company is
currently seeking FDA licensure. The T-SPOT.CMV test and the T-SPOT.PRT test are pipeline products as part of the
Company's fourth intended product line focused on the
transplantation market. In addition to these four product
lines, the Company has additional active development programs in
other immune-regulated conditions. The Company is
headquartered near Oxford, U.K. and in Marlborough, Mass.
Additional information can be found
at www.oxfordimmunotec.com.
T-SPOT and the Oxford Immunotec logo are
trademarks of Oxford Immunotec Ltd. Immunetics is a trademark of
Immunetics, Inc.
CONTACT:
For Media and Investor
Inquiries:
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Oxford Immunotec via Globenewswire
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Oxford Immunotec Global (NASDAQ:OXFD)
Historical Stock Chart
From Sep 2023 to Sep 2024